Skip to main
BDTX

BDTX Stock Forecast & Price Target

BDTX Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Black Diamond Therapeutics Inc. is positioned for significant growth due to its advanced pipeline, particularly with the expected clinical trial results for their therapies, BDTX-4933 and BDTX-1535, which are anticipated to create value inflection points that could elevate their stock value substantially. The company is projected to achieve forecasted sales of approximately $500-750 million if they secure a good Overall Response Rate (ORR) in late 2025, enhancing their attractiveness for potential mergers and acquisitions by leveraging similar-sized oncology market valuations. Additionally, the strong clinical performance of silevertinib, exhibiting a 60% confirmed Overall Response Rate (cORR) across a broad spectrum of patients, reinforces the company's capabilities in targeting actionable mutations—indicating a lucrative opportunity in the first-line non-small cell lung cancer market, projected to exceed $1 billion.

Bears say

Black Diamond Therapeutics Inc. is facing significant challenges regarding the confidence in its clinical pipeline, particularly concerning the performance of its drug, silevertinib, which has shown lower confirmatory objective response rates (cORR) compared to competitors in relevant clinical settings. Additionally, the company's overall market capitalization of approximately $230 million suggests a lack of investor confidence, exacerbated by concerns over the drug's efficacy in a broader patient population and the impact of lowered dosing on treatment effectiveness. Overall, uncertainties related to the drug's competitiveness and efficacy diminish Black Diamond’s financial outlook, indicating potential struggles in gaining traction in the oncology market.

BDTX has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Black Diamond Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Black Diamond Therapeutics (BDTX) Forecast

Analysts have given BDTX a Strong Buy based on their latest research and market trends.

According to 5 analysts, BDTX has a Strong Buy consensus rating as of Feb 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Black Diamond Therapeutics (BDTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.